- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04263311
Scaling Community-Clinical Linkage Models to Address Diabetes and Hypertension Disparities in the Southeast United States
Studieoversikt
Detaljert beskrivelse
The study will provide research training, technical assistance, and capacity-building to community and clinical sites in Georgia for implementation of culturally tailored, evidenced-based CHW programs to improve HTN and diabetes management for South Asians. In addition, the use a multi-theoretical framework to test the effectiveness of a CHW-led intervention compared to usual care among South Asian individuals with diabetes and uncontrolled HTN in Atlanta. The primary outcome is blood pressure control, defined as 130/80 mmHg. It is hypothesized that, compared to usual care, individuals receiving the CHW intervention will be 20% more likely to achieve blood pressure control at 6 months.
And to apply RE-AIM and CFIR frameworks to delineate factors influencing appropriateness, fidelity, adoption, and maintenance of the intervention within clinical and community settings to optimize intervention replication.
In addition, this study will serve as a national information and dissemination resource in the adaptation of evidence-based strategies to reduce geographic disparities in HTN and diabetes across Asian American groups.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10016
- NYU Langone
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
CHW intervention:
Inclusion Criteria:
- identified as of South Asian ethnicity
- are at least 21 years of age and younger than age 75
- had an appointment with a physician or mid-level clinician for routine non-emergent primary care in the last 12 months
- a diagnosis of diabetes
- a diagnosis of hypertension
- an uncontrolled BP reading (>130/80mmHg) in the last 6 months
Provider Surveys Inclusion criteria
- clinicians employed by the clinic
- have enrolled into the study.
Key Informant Interviews Inclusion criteria
- must be a provider, clinic manager, or community health worker.
CHW intervention
Exclusion Criteria:
- under the age of 21 and older than 75
- pregnant
- Type 1 diabetes or diabetes secondary to other conditions
- malignancy or life threatening illness with life expectancy of <5 years
- inability to perform unsupervised physical activity
- diagnosed cognitive deficits or limited decision-making capacity
Provider Surveys Inclusion criteria
- clinicians who are unable to complete the survey in the English language.
Key Informant Interviews Inclusion criteria
- who are unable to participate in the interview conducted in the English language.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Community Health Workers (CHW) treatment group
There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention.
Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention.
Participants enrolled in the intervention will receive monthly text and phone call reminders.
in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers.
Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
|
Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW.
Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan.
Referrals to other services available in the community (i.e.
exercise classes, social services, mental health, tobacco cessation, etc.
|
Ingen inngripen: Control group
There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in BP control
Tidsramme: Baseline Visit, 6 months visits
|
The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) six months following the index office visit.
Individuals receiving care during the implementation of the intervention will be more likely achieve BP control six months following the index office visit than individuals receiving care as usual.
The primary outcome of interest is the proportion of patients who achieve BP control.
this will be measured by the treatment participants and providers surveys.
|
Baseline Visit, 6 months visits
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in Hemoglobin A1c (HbA1c)
Tidsramme: 6 months
|
Change in HbA1c will be measured in participants of CHW intervention versus the control participants.
Clinical data will be retrieved from EHR.
|
6 months
|
Change in systolic blood pressure (SBP)
Tidsramme: 6 months
|
Change in SBP will be measured in participants of CHW intervention versus the control participants.
Clinical data will be retrieved from EHR.
|
6 months
|
Change in diastolic blood pressure (DBP)
Tidsramme: 6 months
|
Change in DBP will be measured in participants of CHW intervention versus the control participants.
Clinical data will be retrieved from EHR.
|
6 months
|
Change in body mass index (BMI)
Tidsramme: 6 months
|
Change in BMI will be measured in participants of CHW intervention versus the control participants.
Clinical data will be retrieved from EHR.
|
6 months
|
Physicians Attitudes Regarding the Integrated Intervention
Tidsramme: Baseline Visit, 6 months
|
Physician attitudes will be primarily assessed with data from brief surveys collected from the participating clinicians.
Survey items with response scales will be designed to capture data on each of the research questions above.
For instance, participants may be asked to respond on a five-point scale (from 1=strongly agree to 5=strongly disagree) to the following statement: "CHWs are helpful tome".
The survey data come from a small sample (n=approximately 10) and are only intended to quantify descriptive information and not for extensive statistical analyses.
The data will be tabulated and summarized descriptively to assess change in attitudes from baseline to 6 months.
|
Baseline Visit, 6 months
|
Barriers and Facilitators to Implementation Adoption and Implications for Scalability
Tidsramme: Baseline Visit, 6 months visit, 12 month visit
|
At baseline, qualitative interviews of key informants will assess current satisfaction and usage of CHWs and organizational workflows.
At follow-up the interviews will assess barriers and facilitators to the implementation and adoption process of the integrated intervention appropriates, fidelity to the interventions and the solicit recommendations for the replication and scalability of the intervention to other sites.
Satisfaction and outcomes from the partnership and capacity building process will also be assessed.
Audio-recordings and interview transcripts will be stripped of all identifying data.
Using a qualitative approach, interview data will be transcribed and analysis will follow "constant comparison" analytic approach.
Using "thematic" coding, initial set of codes will be created which will be reviewed by the CAB to ensure they are relevant and complete.
The coded transcripts will be analyzed with ATLAS.ti, a qualitative data analysis software.
|
Baseline Visit, 6 months visit, 12 month visit
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Nadia Islam, NYU Langone
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 19-01192
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hypertensjon
-
University Hospital of CologneUkjentNAFLD; Hypertensjon, White-Coat Hypertension, Masked HypertensionTyskland
-
Karolinska InstitutetFullførtWhite Coat Hypertension
-
Clinical Hospital Centre ZagrebEuropean Society of HypertensionUkjentWhite Coat Hypertension | Blodtrykk | LivsstilsrisikoreduksjonIsrael, Hellas, Belgia, Tyskland, Armenia, Østerrike, Bulgaria, Kroatia, Tsjekkia, Estland, Italia, Libanon, Litauen, Nederland, Polen, Portugal, Romania, Serbia, Spania, Sverige, Ukraina, Storbritannia
-
Regional Hospital HolstebroFullførtSunn | White Coat Hypertension | Essensiell hypertensjonDanmark
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Aktiv, ikke rekrutterendeWhite Coat Hypertension | Hypertensjon, viktigForente stater
-
University of Alabama at BirminghamTroy UniversityFullførtHypertensjon | Hypertensjon, motstandsdyktig mot konvensjonell terapi | Ukontrollert hypertensjon | Hypertensjon, hvit pelsForente stater
-
PD Dr. Grégoire WuerznerSwiss National Science FoundationFullførtHypertensjon | Overvekt | White Coat Hypertension | Resistent hypertensjonSveits
-
University Hospital, ToursFullførtPTFE-dekkede stenter versus nakne stenter i TIPS (Transjugulær Intra-hepatisk Porto-systemisk shunt)Cirrhotic Portal HypertensionFrankrike
-
Sun Yat-sen UniversityFullførtHepatocellulært karsinom (HCC) | Cirrhotic Portal HypertensionKina
Kliniske studier på CHW
-
Massachusetts General HospitalHar ikke rekruttert ennåHypertensjon | Matusikkerhet | Ernæring, sunn | Felles helsearbeider
-
Ari Johnson, MDHarvard Medical School (HMS and HSDM); University of California, San Francisco og andre samarbeidspartnereFullførtCommunity Health Worker Performance
-
University of MiamiHealth Choice Network; Center for Haitian StudiesFullførtLivmorhalskreftForente stater
-
University of FloridaNational Center for Advancing Translational Sciences (NCATS)Har ikke rekruttert ennå
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)RekrutteringHjertesvikt, KongestivForente stater
-
Public Health - Seattle and King CountyCenters for Disease Control and PreventionFullført
-
Tufts Medical CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Rekruttering
-
University of FloridaFullført
-
University of Illinois at ChicagoPatient-Centered Outcomes Research Institute; University of Chicago; Rush... og andre samarbeidspartnereFullført
-
University of Wisconsin, MadisonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekrutteringDiabetes | Diabetes type 2Forente stater